Struggling to Lose Weight in Henderson? What the Research Says About Medical Weight Loss
The Question We Hear Most Often
“I'm eating right, I'm exercising, and the scale still won't move — what am I missing?” It's the single most common concern we hear from patients walking into Blanqa Medspa in Henderson, and it's rarely about willpower. For a lot of people, weight regulation is driven less by discipline and more by hormonal signaling — specifically, how the body manages hunger, fullness, and blood sugar. That's the gap medical weight loss is designed to address, and it's worth understanding what the research actually shows before deciding if it's right for you.
What Medical Weight Loss Actually Is
Medical weight loss under provider supervision typically centers on GLP-1 receptor agonists — medications that mimic a naturally occurring gut hormone (glucagon-like peptide-1) involved in appetite regulation. These medications slow stomach emptying, increase feelings of fullness, and reduce hunger signaling in the brain, which is why patients often describe eating less without constantly fighting cravings. This is paired with nutritional guidance and ongoing monitoring — not a prescription handed over without follow-up.
What the Research Shows
We'd rather you make this decision with real data than a marketing headline, so here's what's actually been published.
A head-to-head trial called SURMOUNT-5, published in the New England Journal of Medicine in 2025, randomized 751 adults with obesity (without type 2 diabetes) to either tirzepatide or semaglutide for 72 weeks. Tirzepatide produced a mean weight reduction of 20.2%, compared to 13.7% for semaglutide — a statistically significant difference. Both medications produced meaningful, clinically significant weight loss; they simply differ in magnitude, and side effect profiles were similar, with mostly mild-to-moderate gastrointestinal symptoms in both groups.
A 2026 clinical explainer from Stanford Medicine puts those numbers in context: on average, semaglutide produces roughly 15% total body weight loss and tirzepatide roughly 20%, though response varies significantly between individuals — an estimated 10–15% of patients see minimal benefit. Most people reach a plateau somewhere between 12 and 18 months, which reflects the body's normal metabolic adaptation rather than the medication “failing.” Nausea, constipation, and reflux are the most commonly reported side effects, and roughly half of patients nationally discontinue within a year, often due to GI symptoms that could often be better managed with proper dose titration.
In December 2025, the World Health Organization issued its first global guideline on GLP-1 medicines for obesity, conditionally recommending them for long-term use in adults with obesity — but explicitly paired with structured diet and physical activity support, not as a standalone fix. The WHO was direct that the recommendation is conditional due to limited long-term safety data, cost barriers, and the risk of unsupervised or unregulated use, and it specifically called for qualified healthcare provider oversight throughout treatment. That guidance lines up with how we approach it clinically: this is a medical treatment that works best with a provider actively managing your dose, your labs, and your progress — not a set-it-and-forget-it injection.
Who Tends to Benefit — and Who Should Hold Off
Based on the clinical literature, the best candidates are typically adults with a BMI in the obesity range, or with excess weight alongside a related condition like prediabetes, type 2 diabetes, high blood pressure, sleep apnea, or fatty liver disease. These medications are generally not appropriate for anyone with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, and they're not used during pregnancy. This is exactly the kind of history that needs to be reviewed one-on-one before starting anything — which is why an intake consultation, not a quick sign-up form, is the right first step.
What to Expect: Timeline, Side Effects, and Plateaus
If you start medical weight loss, expect a gradual dose titration schedule designed to minimize nausea and GI upset while your body adjusts. Meaningful results build over months, not days, and a plateau after the first year or so is common and expected rather than a sign something's wrong. What separates a good outcome from a frustrating one is usually the follow-up: adjusting the dose, addressing side effects early, and pairing the medication with realistic nutrition guidance rather than expecting the injection to do all the work alone.
Why This Isn't a DIY Decision
Between telehealth ads and social media, it's easy to assume these medications are simple and interchangeable. In practice, dosing, monitoring, and managing side effects safely is exactly why the WHO guideline calls for supervised care — and why we treat every weight loss patient at Blanqa as an ongoing relationship, not a one-time transaction. If diet and exercise alone haven't moved the needle and you're curious whether medical weight loss makes sense for your health history, we'd rather walk through the real data with you than have you guess based on an ad.
Book a Consultation
Every patient's history, goals, and health picture are different, and nothing above should be read as a personal recommendation — that's exactly what a consultation is for. Bring your questions, and we'll help you figure out whether medical weight loss, or another approach entirely, fits your goals.
About the Author
Bianca Camille Fong, APRN, FNP-BC, is a board-certified Family Nurse Practitioner
Founder & CEO of Fong Precision Care (Primary Care and Medical exams) and Blanqa Medspa (Wellness and Aesthetics), both in Henderson, NV.
Blanqa Medspa
1485 West Warm Springs Road, Suite 109 B, Henderson, NV 89014
Phone: 702-997-6764 | Email: hello@blanqaLV.com
Sources
1. SURMOUNT-5 Trial. “Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.” New England Journal of Medicine, 2025. https://www.nejm.org/doi/abs/10.1056/NEJMoa2416394
2. “GLP-1s 101: What the science says about weight loss, side effects, safety.” Stanford Medicine, 2026. https://med.stanford.edu/news/insights/2026/06/glp1s-101-weight-loss-wegovy-ozempic-zepbound-side-effects-safe-use.html
3. “WHO issues global guideline on the use of GLP-1 medicines in treating obesity.” World Health Organization, December 2025. https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity